Search company, investor...
EUCODIS Bioscience company logo

EUCODIS Bioscience

Founded Year



Acquired | Acquired

About EUCODIS Bioscience

EUCODIS Bioscience provides enzyme solutions for specific applications in biopharma, fine chemicals, food and feed, and cosmetics. It was founded in 2007 and is based in Vienna, Austria. On August 2nd, 2022, EUCODIS Bioscience was acquired by Biosynth Carbosynth. The terms of the transaction were not disclosed.

Headquarters Location

Viehmarktgasse 2 a

Vienna, 1030,


Missing: EUCODIS Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EUCODIS Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

EUCODIS Bioscience Patents

EUCODIS Bioscience has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Environmental microbiology, Burkholderiales, Microbiology, Bacteria, Disinfectants


Application Date


Grant Date



Related Topics

Environmental microbiology, Burkholderiales, Microbiology, Bacteria, Disinfectants



Latest EUCODIS Bioscience News

Schoenherr Advises on Eucodis Bioscience Sale to Biosynth Group

Nov 2, 2022

Details Details Details Default Helvetica Segoe Georgia Times Share This Schoenherr has advised the shareholders of Vienna-headquartered biotech company Eucodis Bioscience on the sale of the company to the Biosynth Group. Biosynth is a Swiss life sciences reagents, custom synthesis, and manufacturing services company specializing in complex chemistry, peptides, and key biological raw materials. According to Schoenherr , “Eucodis is an expert in engineering and developing enzymes for pharma, biotech, and applied markets. The transaction involved the coordination of a total of 19 sellers and structuring and implementing the concurrent termination and payoff of equity participation instruments. It closed on October 17, 2022, after the transaction received the required FDI clearance.” Schoenherr ’s team included Partners Robert Bachner and Dominik Hofmarcher, Counsel Marco Thorbauer, Attorney at Law Daniel Wadl, and Associate Leonhard Telsnig.

EUCODIS Bioscience Frequently Asked Questions (FAQ)

  • When was EUCODIS Bioscience founded?

    EUCODIS Bioscience was founded in 2007.

  • Where is EUCODIS Bioscience's headquarters?

    EUCODIS Bioscience's headquarters is located at Viehmarktgasse 2 a, Vienna.

  • What is EUCODIS Bioscience's latest funding round?

    EUCODIS Bioscience's latest funding round is Acquired.

  • Who are the investors of EUCODIS Bioscience?

    Investors of EUCODIS Bioscience include Biosynth Carbosynth, IBG Beteiligungsgesellschaft, Gamma Capital Partners, Pontis Venture Partners, iLab 24 Mittelstandsfinanzierungs and 5 more.

  • Who are EUCODIS Bioscience's competitors?

    Competitors of EUCODIS Bioscience include CellCentric, Echelon Biosciences, Sword Diagnostics, Ensemble Therapeutics, IntelliCyt and 10 more.

Compare EUCODIS Bioscience to Competitors

Fluxion Biosciences Logo
Fluxion Biosciences

Fluxion Biosciences is a developer of precision solutions for life science research and diagnostics. Fluxion's liquid biopsy solutions are changing how cancer is detected and treated. Fluxion's pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion's technologies are used globally by cancer centers developing new tests for early cancer detection and patient monitoring.

Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

Cira Discovery Sciences

Cira Discovery Sciences, Inc. was founded in 2003 and funded by BioAdvance in 2004 with the mission of discovering biomarker patterns for medical diagnostic products and drug discovery services. The company targets two key application domains, proteomics and flow cytometry, both utilized in the diagnostic and pharmaceutical fields. Cira has developed and patented methods of computational analysis of large, high-dimensionality data sets characteristic of both proteomics and flow cytometry. Advances in these fields are currently hampered by limitations in extracting valuable patentable knowledge from the data. The company ceased operations in 2008 and its intellectual property is being marketed for acquisition.


ConjuGon is focused on developing fundamentally new products to eliminate bacterial infections. ConjuGon was founded in 2001, to develop and commercialize a novel, conjugation-based antibacterial technology discovered at the University of Wisconsin-Madison. The primary clinical purpose of products based on this technology will be to prevent and eliminate antibiotic-resistant, bacterial infections of the skin and soft tissues including traumatic injury, surgical, and burn wounds. The company has also in-licensed from Baylor University, an innovative technology to prevent catheter-associated urinary tract infections. Presently, ConjuGon performs most of its Research and Development operations at its corporate headquarters in Madison, WI and contracts with leading pharmaceutical, manufacturing, clinical research and regulatory experts nationwide to advance its products.

Nanion Technologies GmbH

Nanion Technologies is a spin-off company from the Center of Nanoscience (CeNS) of the University of Munich (LMU). anion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. anion bases its business on a chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for medicines aimed at many important diseases.

Firebird Biomolecular Sciences

Firebird Biomolecular Sciences, Inc. supplies nucleic acid components, libraries, polymerases and software to support human diagnostics, synthetic biology and human therapy. A partner with the Foundation for Applied Molecular Evolution (FfAME), Firebird aims to provide a scientific, research-based environment to help create a more integrated science for the current century and to transfer technologies from basic research into products and processes to meet commercial and medical needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.